This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Cholesterol lowering therapy

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Cholesterol-lowering therapy is an area of medicine that has prompted heated debate and a great deal of confusion.

Hypercholesterolaemia treatment can be considered in terms of primary and secondary prevention of coronary heart disease.

In general, the treatment of choice for raised cholesterol is a statin.

NICE state that (1):

  • before offering lipid modification therapy for primary prevention, all other modifiable CVD risk factors should be considered and their management optimised if possible. Baseline blood tests and clinical assessment should be performed, and comorbidities and secondary causes of dyslipidaemia should be treated. Assessment should include:
    • smoking status
    • alcohol consumption
    • blood pressure
    • body mass index or other measure of obesity
    • fasting total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides (if fasting levels are not already available)
    • fasting blood glucose
    • renal function
    • liver function (transaminases)
    • thyroid-stimulating hormone (TSH) if dyslipidaemia is present

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.